Clark Andrew L, Pellicori Pierpaolo
Hull York Medical School, Castle Hill Hospital, Castle Road, Cottinham, Kingston upon Hull, HU16 5JQ, UK.
ESC Heart Fail. 2014 Dec;1(2):82-86. doi: 10.1002/ehf2.12012. Epub 2014 Nov 24.
This article provides an overview of trials relevant to the pathophysiology, prevention, and treatment of heart failure, presented at the European Society of Cardiology meeting held in Barcelona in autumn 2014. Trials reported here include PARADIGM-HF (LCZ696 versus enalapril in heart failure), CONFIRM-HF (treatment of iron deficiency in heart failure), and SIGNIFY (ivabradine in patients with stable coronary artery disease). In addition, we discuss recent developments in the treatment of atrial fibrillation and the lack of benefit with the use of beta-blockers in these patients. Finally, the article describes recent advances in the use of vagal stimulation in patients with heart failure. © 2014 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
本文概述了在2014年秋季于巴塞罗那举行的欧洲心脏病学会会议上所展示的、与心力衰竭的病理生理学、预防及治疗相关的试验。此处报告的试验包括PARADIGM-HF（在心力衰竭中比较LCZ696与依那普利）、CONFIRM-HF（心力衰竭中铁缺乏的治疗）以及SIGNIFY（稳定型冠状动脉疾病患者使用伊伐布雷定）。此外，我们还讨论了心房颤动治疗方面的最新进展以及这些患者使用β受体阻滞剂缺乏获益的情况。最后，本文描述了心力衰竭患者使用迷走神经刺激的最新进展。© 2014作者。《ESC心力衰竭》由John Wiley & Sons Ltd代表欧洲心脏病学会出版。
